Rating Change
Truist Securities reiterated its Buy rating on Arcus Biosciences, Inc. (NYSE:RCUS) on October 21, 2026.
reiterateNYSE:RCUS
Truist Securities Reiterates Buy Rating on Arcus Biosciences, Inc. (RCUS)
Truist Securities reiterated its Buy rating on Arcus Biosciences, Inc. (NYSE:RCUS) on October 21, 2026.
At publication ·
What changed
Arcus Biosciences, Inc. (NYSE:RCUS) · reiterate
- Firm
- Truist Securities
- Rating
- Buy to Buy
- Price at event
- $19.41
- Market capitalization
- $2.7B
At a glance
Key takeaways
- Truist Securities reiterated a Buy rating on Arcus Biosciences (RCUS) on October 21, 2026, with the stock trading at $19.41 and a market cap of $2.7 billion.
Market Context
Arcus Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $19.41 with a market capitalization of $2.7B. The stock has gained 44.2% over the past 52 weeks.
Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arcus Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Arcus Biosciences, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 21, 2026 | Wedbush | Outperform | N/A |
| Oct 21, 2026 | Truist Securities | Buy | N/A |
| Oct 16, 2026 | William Blair | Outperform | N/A |
| Oct 14, 2026 | JP Morgan | Overweight | N/A |
| Sep 30, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RCUS Stock Page
Frequently Asked Questions
What does the Buy rating mean for RCUS?
A rating of Buy from Truist Securities reflects the analyst's outlook on Arcus Biosciences, Inc. (NYSE:RCUS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RCUS forecast page.